Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An opportunity for pharmacists

Am J Health Syst Pharm. 2022 Jan 1;79(1):e65-e70. doi: 10.1093/ajhp/zxab271.
No abstract available

Keywords: SGLT2 inhibitor; diabetic kidney disease; kidney outcomes; multidisciplinary care; pharmacist intervention.

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / epidemiology
  • Humans
  • Pharmacists
  • Renal Insufficiency, Chronic* / drug therapy
  • Renal Insufficiency, Chronic* / epidemiology
  • Sodium-Glucose Transporter 2 Inhibitors*


  • Sodium-Glucose Transporter 2 Inhibitors